Affectis Pharmaceuticals AG is a pharmaceuticals company developing novel drugs for the treatment of neurodegenerative and neuroinflammatory diseases.
Affectis' capabilities in drug discovery and medicinal chemistry allowed the company to develop drugs with innovative mechanisms of action based on pioneering findings in the field of P2X7 receptors.
Affectis started operations in January 2004 as a spin-off from the Max Planck Institute of Psychiatry. The company’s founders include Florian Holsboer, a key opinion leader in psychiatry, Wolfgang Wurst, an expert in mouse genetics, and Herbert Stadler, a serial biotech entrepreneur.
Since January 2014 Affectis has relocated to Dortmund, Germany, and is now fully owned by and closely collaborating with the Lead Discovery Center GmbH (LDC) to further advance its core asset AFC-5128.
In 2020, Affectis entered a collaboration with the KHAN Technology Transfer Fund I (KHAN-I).